Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04757116 · ClinicalTrials.gov registry record · NA

Post-Market Study to Assess iTind Safety in Comparison to UroLift

A NA study of Benign Prostatic Hyperplasia (BPH), sponsored by Olympus Corporation of the Americas.

Recruiting
Registry status
NA
Development phase
206
Enrollment target
18
Study locations

NCT04757116 is a NA study of Benign Prostatic Hyperplasia (BPH) that is actively recruiting participants, run by Olympus Corporation of the Americas. The registered enrollment target is 206 participants, above the 45-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (358% higher). The trial reports 18 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04757116, a NA study of Benign Prostatic Hyperplasia (BPH), is actively recruiting participants, sponsored by Olympus Corporation of the Americas.

RECRUITING
Registry status
NA
Development phase
206 participants
Enrollment target
18
Study locations

Study Summary

The study objective is to evaluate the safety of the iTind device comparied to UroLift.

Interventions

  • DEVICE iTind
  • PROCEDURE UroLift

Study Locations (18)

Texas

  • Midtown Urology Associates - Austin
  • Houston Metro Urology - Houston
  • The Urology Place - San Antonio

Other

  • Queen Margaret Hospital - Dunfermline
  • Frimley Park Hospital - London
  • Norfolk & Norwich University Hospital - Norwich

Arizona

  • Mayo Clinic Arizona - Phoenix
  • Arizona Urology Specialists - Tucson

California

  • Urology Associates of Central California - Fresno
  • Golden State Urology - Sacramento

Illinois

  • NorthShore University Health System Research Institute - Evanston

Louisiana

  • Southeast Louisiana Veterans Health Care System - New Orleans

Minnesota

  • Minnesota Urology - Woodbury

Nebraska

  • Adult & Pediatric Urology - Omaha

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2022-09-26
Est. Completion 2031-12-31
Phase NA

What the Registry Record Tells You About NCT04757116

The ClinicalTrials.gov registry entry for NCT04757116 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 45-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (358% higher). The listed sponsor is Olympus Corporation of the Americas, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Benign Prostatic Hyperplasia (BPH) appearing as the primary indexed condition, and to 2 interventions - of which iTind is the first listed.

NCT04757116 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Texas, Other, Arizona.

Frequently Asked Questions

What is clinical trial NCT04757116 about?

NCT04757116 is a clinical study titled "Post-Market Study to Assess iTind Safety in Comparison to UroLift". The study objective is to evaluate the safety of the iTind device comparied to UroLift.

What is the current status of trial NCT04757116?

This trial is currently recruiting. It is a NA study. The enrollment target is 206 participants. The study started on 2022-09-26. Estimated completion is 2031-12-31.

What conditions does trial NCT04757116 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia (BPH).

What interventions are being tested in trial NCT04757116?

The interventions under investigation include: iTind (DEVICE), UroLift (PROCEDURE).

Who is sponsoring clinical trial NCT04757116?

This trial is sponsored by Olympus Corporation of the Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04757116 being conducted?

This trial has 18 study locations across Arizona, California, Illinois, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Benign Prostatic Hyperplasia (BPH)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.